Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8693938 | 0.68 | — | — | |
| SCHEMBL101638 | 0.68 | — | — | |
| SCHEMBL11204445 | 0.67 | ALDH1A1 (0.39) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL22206279 | 0.66 | — | — | |
| SCHEMBL6260959 | 0.66 | — | — | |
| SCHEMBL5838655 | 0.66 | — | — | |
| SCHEMBL12075530 | 0.65 | MEN1 (0.36) | KMT2ARAB9AMEN1SMN1; SMN2POLB | |
| SCHEMBL14820155 | 0.64 | HTR1A (0.31) | — | |
| SCHEMBL12598652 | 0.64 | CCR1 (0.37) | KMT2ARAB9AMEN1SMN1; SMN2POLB | |
| SCHEMBL12598648 | 0.64 | CCR1 (0.37) | KMT2ARAB9AMEN1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111902401-B | Receptor inhibitors, pharmaceutical compositions comprising the same and uses thereof | 北京泰德制药股份有限公司 | 2023-06-13 | — | — | CN | claimed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | claimed |
| US-20080255092-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | claimed |
| US-3957984-A | ANTIBACTERIAL, ANTIBIOTICS | SMITHKLINE CORPORATION (US) | 1976-05-18 | — | — | US | claimed |
| JP-51125398-A | — | — | None | — | — | JP | disclosed |
| EP-4373836-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693517-A | Novel compounds and compositions for targeted treatment of renal cancer | 上海盟科药业股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117642419-A | Compounds and compositions for targeted treatment of kidney disease | 上海盟科药业股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023116734-A1 | FUSED PYRROLIDINE COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY VIRAL INFECTIONS | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-06-29 | — | — | WO | disclosed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2023001224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001223-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| US-20030186975-A1 | Coumarin derivatives with comt inhibiting activity | PYSTYNEN JARMO (FI) | 2003-10-02 | — | — | US | disclosed |
| WO-2003066631-A1 | ANTIMICROBIAL THIADIAZINONE DERIVATIVES USEFUL IN TREATMENT OF BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1301503-A1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2003-04-16 | — | — | EP | disclosed |
| US-6344209-B1 | BIODEGRADABLE POLYLACTIC ACID, POLYGLYCOLIC ACID AND COPOLYMERS OF THE TWO FOR BONE DISEASES THERAPY; ANTIBIOTICS, ANTI-INFLAMMATORY AND ANTI-TUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| WO-2002002548-A1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2002-01-10 | — | — | WO | disclosed |
| EP-1028946-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| JP-S51125398-A | A PROCESS FOR PREPARING 7-SUBSTITUTED ALKANAMIDE-3-SUBSTITUTED THIOMET HYL-3-CEPHEM-4-CARBOXYLIC ACIDS | FUJISAWA PHARMACEUT CO LTD | 1976-11-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255092-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR3C, HTR3A | KMT2A 1869/4885RAB9A 1847/4885MEN1 2734/4885 |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR1A, HTR2A | KMT2A 1221/4885RAB9A 2004/4885MEN1 4387/4885 |
| US-20030186975-A1 | Coumarin derivatives with comt inhibiting activity | COMT, CYP1A1, CYP2D6 | KMT2A 2987/4885RAB9A 1341/4885MEN1 3772/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KMT2A 2683/4885RAB9A 490/4885MEN1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.